Innate or adaptive resistance to ALK inhibitors often leads to short-term and/or minimal responses in ALK-aberrant neuroblastoma tumors, thus impacting their potential utility for long-term use as single agents in patients with neuroblastoma. The gene discussed is ALK; the disease is neuroblastoma.